Opus Genetics (IRD) vs Phathom Pharmaceuticals (PHAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Opus Genetics (IRD) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, gaining 108.9% versus a loss of 68.9%. Over five years, IRD leads with a -8.3% price change compared with -76.5% for PHAT. Opus Genetics is the larger company by market cap ($385.7 million vs $378.8 million), about 1.0 times the size, while Phathom Pharmaceuticals is growing revenue faster (+216.9% vs +29.1%).
Phathom Pharmaceuticals converts more of its revenue into profit, with a net margin of -126.3% versus -349.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRD | PHAT |
|---|---|---|
| Share price | $3.99 | $4.66 |
| Market cap | $385.65M | $378.82M |
| 1-day change | -2.21% | -8.27% |
| YTD return | +98.51% | -71.91% |
| 1-year return | +108.90% | -68.93% |
| 5-year return | -8.28% | -76.46% |
| Forward P/E | — | 5.18 |
| EPS (TTM) | $-1.48 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $14.20M | $175.11M |
| Revenue growth (YoY) | +29.15% | +216.93% |
| Net income (latest FY) | $-49.59M | $-221.25M |
| Gross margin | — | 87.09% |
| Operating margin | -271.90% | -91.36% |
| Net margin | -349.33% | -126.35% |
| 52-week high | $7.07 | $18.31 |
| 52-week low | $1.88 | $4.62 |
| Distance from 52-week high | -43.56% | -74.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +249.37% | +321.67% |
| Average volume | 2.56M | 1.45M |
| Shares outstanding | 96.65M | 81.29M |
| Employees | 27 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRD has outperformed PHAT by 177.8 percentage points over the past year.
- Phathom Pharmaceuticals is more profitable, keeping -126.3 cents of every revenue dollar as net income versus -349.3 cents for Opus Genetics.
- Phathom Pharmaceuticals grew revenue faster in its latest fiscal year (+216.93% vs +29.15%).
About Opus Genetics
IRD stock →Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees
IRD vs PHAT FAQ
Which is bigger, Opus Genetics or Phathom Pharmaceuticals?
Opus Genetics (IRD) is larger, with a market capitalization of $385.65M compared with $378.82M for Phathom Pharmaceuticals (PHAT).
Which stock has performed better over the past year, IRD or PHAT?
IRD returned +108.90% over the past 12 months, compared with -68.93% for PHAT (price return, excluding dividends). Past performance does not predict future results.
Are Opus Genetics and Phathom Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.